Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takeshi Tomoda is active.

Publication


Featured researches published by Takeshi Tomoda.


Journal of Gastroenterology and Hepatology | 2011

Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.

Koji Miyahara; Kazuhiro Nouso; Takeshi Tomoda; Sayo Kobayashi; Hiroaki Hagihara; Kenji Kuwaki; Junichi Toshimori; Hideki Onishi; Fusao Ikeda; Yasuhiro Miyake; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Kazuhide Yamamoto

Background and Aim:  Sorafenib, the first agent demonstrated to have efficacy to improve the survival of patients with advanced hepatocellular carcinoma (HCC), is an active multikinase inhibitor affecting angiogenesis and tumor proliferation. We analyzed cytokines related to angiogenesis or cell proliferation, and tried to determine their utility as biomarkers of sorafenib treatment effect for HCC.


Journal of Gastroenterology and Hepatology | 2012

Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: A case control study

Takeshi Tomoda; Kazuhiro Nouso; Akiko Sakai; Mamoru Ouchida; Sayo Kobayashi; Koji Miyahara; Hideki Onishi; Shinichiro Nakamura; Kazuhide Yamamoto; Kenji Shimizu

Backgroud and Aim:  Chronic hepatitis C virus (HCV) infection is a well known risk factor for hepatocellular carcinoma (HCC). The aim of this study is to elucidate the genetic risk of development and recurrence of HCC in patients with HCV.


Endoscopy | 2015

Contrast-enhanced harmonic endoscopic ultrasonography with time-intensity curve analysis for intraductal papillary mucinous neoplasms of the pancreas.

Naoki Yamamoto; Hironari Kato; Takeshi Tomoda; Kazuyuki Matsumoto; Ichiro Sakakihara; Yasuhiro Noma; Shigeru Horiguchi; Ryo Harada; Koichiro Tsutsumi; Keisuke Hori; Takehiro Tanaka; Hiroyuki Okada; Kazuh de Yamamoto

BACKGROUND AND STUDY AIMS Preoperative diagnosis of the pathological grade of intraductal papillary mucinous neoplasms (IPMNs) is difficult. This study aimed to evaluate the accuracy of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) with time - intensity curve analysis in differentiating between low or intermediate grade dysplasia (LGD/IGD) and high grade dysplasia or invasive carcinoma (HGD/invasive carcinoma) in IPMNs and to assess correlation between the time - intensity curve parameters and tumor microvessel density. PATIENTS AND METHODS Data from 30 patients with resected IPMNs (14 LGD/IGD, 16 HGD/invasive carcinoma) who underwent CH-EUS with time - intensity curve analysis were evaluated retrospectively. Time - intensity curve parameters and the microvessel density of the mural nodule were compared between the HGD/invasive carcinoma and LGD/IGD groups; the diagnostic accuracy of the time - intensity curve parameters was evaluated. RESULTS The echo intensity change and echo intensity reduction rate of the mural nodule, and the nodule/pancreatic parenchyma contrast ratio were significantly higher in the HGD/invasive carcinoma group than in the LGD/IGD group (P < 0.05); the accuracies of these parameters were 80 %, 86.7 %, and 93.3 %, respectively. The microvessel density of the mural nodule was significantly higher in the HGD/invasive carcinoma group (P = 0.002). There was a strong positive, linear correlation between the echo intensity change of the mural nodule and the microvessel density (r = 0.803, P < 0.001). CONCLUSIONS CH-EUS with time - intensity curve analysis is potentially useful for quantitatively evaluating the blood flow of IPMN microvasculature, and for differentiating between HGD/invasive carcinoma and LGD/IGD.


Journal of Gastroenterology and Hepatology | 2013

Prognotic impact of serum follistatin in patients with hepatocellular carcinoma

Takeshi Tomoda; Kazuhiro Nouso; Koji Miyahara; Sayo Kobayashi; Hideaki Kinugasa; Junki Toyosawa; Hiroaki Hagihara; Kenji Kuwaki; Hideki Onishi; Shinichiro Nakamura; Fusao Ikeda; Yasuhiro Miyake; Hidenori Shiraha; Akinobu Takaki; Kazuhide Yamamoto

Follistatin (FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates a variety of processes during tumor progression. Here, serum FST in patients with liver diseases was measured, and its clinical utility as a biomarker was assessed.


Hepatology Research | 2012

Evaluation of the effect of sorafenib using serum NX‐des‐γ‐carboxyprothrombin in patients with hepatocellular carcinoma

Koji Miyahara; Kazuhiro Nouso; Yuki Morimoto; Takeshi Tomoda; Sayo Kobayashi; Yasuto Takeuchi; Hiroaki Hagihara; Kenji Kuwaki; Hideki Ohnishi; Fusao Ikeda; Yasuhiro Miyake; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Kazuhide Yamamoto

Des‐γ‐carboxyprothrombin (DCP) is known to be increased by the use of sorafenib for the treatment of hepatocellular carcinoma (HCC), despite its therapeutic efficacy. In addition to the tumor progression, hypoxia that impairs vitamin K uptake is known to induce DCP and this mechanism may explain DCP elevation by sorafenib. In this study, we tried to evaluate the effect of sorafenib treatment using a new marker, NX‐DCP, which is specific to vitamin K absence.


Digestive Endoscopy | 2017

Long-term outcomes and risk factors of biliary stent dysfunction after endoscopic double stenting for malignant biliary and duodenal obstructions

Kazuyuki Matsumoto; Hironari Kato; Koichiro Tsutsumi; Sho Mizukawa; Syuntaro Yabe; Hiroyuki Seki; Yutaka Akimoto; Daisuke Uchida; Takeshi Tomoda; Naoki Yamamoto; Shigeru Horiguchi; Kenji Kuwaki; Hiroyuki Okada

Few reports describe the endoscopic double‐stenting procedure for malignant biliary and duodenal obstructions. We evaluated the clinical outcomes from double stenting, and analyzed the risk factors for biliary stent dysfunction following double stenting.


Digestive Endoscopy | 2017

Predictive factors for outcomes of patients undergoing endoscopic therapy for bile leak after hepatobiliary surgery

Shuntaro Yabe; Hironari Kato; Sho Mizukawa; Yutaka Akimoto; Daisuke Uchida; Hiroyuki Seki; Takeshi Tomoda; Kazuyuki Matsumoto; Naoki Yamamoto; Shigeru Horiguchi; Koichiro Tsutsumi; Hiroyuki Okada

Endoscopic procedures are used as first‐line treatment for bile leak after hepatobiliary surgery. Advances have been made in endoscopic techniques and devices, but few reports have described the effectiveness of endoscopic procedures and the management principles based on severity of bile leak. We evaluated the effectiveness of an endoscopic procedure for the treatment of bile leak after hepatobiliary surgery.


World Journal of Gastroenterology | 2012

Partial stent-in-stent placement of biliary metallic stents using a short double-balloon enteroscopy.

Koichiro Tsutsumi; Hironari Kato; Takeshi Tomoda; Kazuyuki Matsumoto; Ichiro Sakakihara; Naoki Yamamoto; Yasuhiro Noma; Takayuki Sonoyama; Hiroyuki Okada; Kazuhide Yamamoto

Endoscopic intervention is less invasive than percutaneous or surgical approaches and should be considered the primary drainage procedure in most cases with obstructive jaundice. Recently, therapeutic endoscopic retrograde cholangiopancreatography (ERCP) using double-balloon enteroscopy (DBE) has been shown to be feasible and effective, even in patients with surgically altered anatomies. On the other hand, endoscopic partial stent-in-stent (PSIS) placement of self-expandable metallic stents (SEMSs) for malignant hilar biliary obstruction in conventional ERCP has also been shown to be feasible, safe and effective. We performed PSIS placement of SEMSs for malignant hilar biliary obstruction due to liver metastasis using a short DBE in a patient with Roux-en-Y anastomosis and achieved technical and clinical success. This procedure can result in quick relief from obstructive jaundice in a single session and with short-term hospitalization, even in patients with surgically altered anatomies.


Transplantation | 2016

Biliary Anastomotic Stricture After Adult Living Donor Liver Transplantation With Duct-to-Duct Reconstruction: Outcome After Endoscopic Treatment Including Rendezvous Procedure.

Takeshi Tomoda; Hironari Kato; Sho Mizukawa; Syuntaro Yabe; Yutaka Akimoto; Hiroyuki Seki; Daisuke Uchida; Kazuyuki Matsumoto; Naoki Yamamoto; Shigeru Horiguchi; Koichiro Tsutsumi; Hiroyuki Okada

Background To evaluate the outcomes and investigate the factors associated with restricture after endoscopic treatment. Methods Between April 2001 and July 2014, 98 patients experienced biliary anastomotic stricture (BAS) after living donor liver transplantation (LDLT) with duct-to-duct reconstruction, and all were first referred to Okayama University Hospital for endoscopic stent deployment. When deployment was unsuccessful, a percutaneous transhepatic procedure was used. Treatment outcomes, including stricture resolution, BAS recurrence, and risk factors of BAS recurrence, were evaluated retrospectively. Results Successful stent deployment was achieved in 90 of 98 patients (91.8%) by both procedures. Among the 90 patients, stricture resolution was eventually observed in 72. The median number of endoscopic retrograde cholangiographies performed was 5. After a median follow-up period of 48.8 months from stent removal, BAS recurrence that required intervention occurred in 22 patients (30.6%). In multivariate analysis, portal vein stenosis after LDLT was associated with BAS recurrence after endoscopic treatment (P = 0.03). Among the 22 patients who required reintervention, 16 (73%) had their stents removed, and recurrence after retreatment occurred in 3 patients (18.8%). Conclusions Endoscopic treatment is a useful procedure for the treatment for BAS after LDLT with duct-to-duct reconstruction. Portal vein stenosis may be one of the risks associated with the recurrence of BAS.


Internal Medicine | 2016

Pancreatic Hepatoid Carcinoma Mimicking a Solid Pseudopapillary Neoplasm: A Challenging Case on Endoscopic Ultrasound-guided Fine-needle Aspiration.

Yutaka Akimoto; Hironari Kato; Kazuyuki Matsumoto; Ryo Harada; Shinsuke Oda; Soichiro Fushimi; Shou Mizukawa; Shuntaro Yabe; Daisuke Uchida; Hiroyuki Seki; Takeshi Tomoda; Naoki Yamamoto; Shigeru Horiguchi; Koichiro Tsutsumi; Takahito Yagi; Hiroyuki Okada

A 59-year-old man was admitted to our hospital for treatment of a 45 mm pancreatic mass found during a medical examination. Endoscopic ultrasound-guided fine-needle aspiration cytology showed polygonal cells with pseudopapillary structures. The tumor cells were positive for nuclear/cytoplasmic β-catenin and CD10, and negative for chromogranin A. After a tentative diagnosis of a solid pseudopapillary neoplasm, middle pancreatectomy was performed. Histologically, polygonal cells with abundant eosinophilic cytoplasm formed in the trabeculae and were immunohistochemically positive for HepPar1 and protein induced by vitamin K absence or antagonist-II. The tumor was finally diagnosed to be pancreatic hepatoid carcinoma. No recurrence occurred for 12 months, even without adjuvant chemotherapy.

Collaboration


Dive into the Takeshi Tomoda's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge